Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Real Time Quote from BATS)

$13.78 USD

13.78
635,200

-0.37 (-2.62%)

Updated Dec 11, 2023 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.96%
2Buy17.61%
3Hold8.96%
4Sell4.80%
5Strong Sell2.32%
S&P50010.64%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CPRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Catalyst Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Assets          
Cash & Equivalents 298 191 140 95 53
Receivables 10 7 6 11 0
Notes Receivable 0 0 0 0 0
Inventories 7 8 5 2 0
Other Current Assets 5 4 8 4 2
Total Current Assets 321 210 159 111 55
Net Property & Equipment 1 1 0 0 0
Investments & Advances 0 0 0 0 5
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 19 24 33 0 0
Intangibles 32 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 376 238 192 112 60
Liabilities & Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Notes Payable 0 0 0 0 0
Accounts Payable 4 3 4 4 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 54 24 19 20 7
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 58 27 23 24 10
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 14 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 75 31 23 25 10
Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 250 233 223 216 211
Retained Earnings 50 -26 -54 -129 -161
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 300 207 170 88 51
Total Liabilities & Shareholder's Equity 376 238 192 112 60
Total Common Equity 300 207 170 88 51
Shares Outstanding 104.00 103.10 103.60 103.00 102.70
Book Value Per Share 2.89 2.01 1.64 0.85 0.49

Fiscal Year End for Catalyst Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Assets          
Cash & Equivalents 121 179 148 298 256
Receivables 48 43 33 10 9
Notes Receivable 0 0 0 0 0
Inventories 9 11 10 7 7
Other Current Assets 14 9 7 5 4
Total Current Assets 192 241 199 321 276
Net Property & Equipment 1 1 1 1 1
Investments & Advances 13 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 37 23 20 19 20
Intangibles 167 176 184 32 33
Deposits & Other Assets 0 0 0 0 0
Total Assets 413 444 407 376 333
Liabilities & Shareholders Equity 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Notes Payable 0 0 0 0 0
Accounts Payable 5 4 3 4 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 53 48 53 54 42
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 58 53 57 58 45
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 4 13 14 15
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 65 69 74 75 63
Shareholders Equity 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 262 258 254 250 246
Retained Earnings 86 117 79 50 24
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 349 375 334 300 270
Total Liabilities & Shareholder's Equity 413 444 407 376 333
Total Common Equity 349 375 334 300 270
Shares Outstanding 106.50 106.50 105.60 104.00 102.80
Book Value Per Share 3.27 3.52 3.16 2.89 2.63